These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11706701)

  • 1. Factor VIII inhibitor with catalytic activity towards factor VIII.
    Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Horn MP; Kazatchkine MD; Kaveri SV
    Chem Immunol; 2000; 77():102-14. PubMed ID: 11706701
    [No Abstract]   [Full Text] [Related]  

  • 2. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
    Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
    Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic antibodies against factor VIII in hemophilia A.
    Stollar BD
    N Engl J Med; 2002 Feb; 346(9):702-3. PubMed ID: 11870249
    [No Abstract]   [Full Text] [Related]  

  • 4. Catalytic antibodies to factor VIII in haemophilia A.
    Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S31-4. PubMed ID: 14567533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of proteolytic antibodies against factor VIII in hemophilia A.
    Lacroix-Desmazes S; Bayry J; Misra N; Horn MP; Villard S; Pashov A; Stieltjes N; d'Oiron R; Saint-Remy JM; Hoebeke J; Kazatchkine MD; Reinbolt J; Mohanty D; Kaveri SV
    N Engl J Med; 2002 Feb; 346(9):662-7. PubMed ID: 11870243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII inhibitor with catalytic activity towards factor VIII.
    Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Kazatchkine MD; Kaveri SV
    Haematologica; 2000 Oct; 85(10 Suppl):89-92. PubMed ID: 11187883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to factor VIII with catalytic activity.
    Bayry J; Lacroix-Desmazes S; Pashov A; Stahl D; Hoebeke J; Kazatchkine MD; Kaveri SV
    Autoimmun Rev; 2003 Jan; 2(1):30-5. PubMed ID: 12848973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
    Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe bleeding in hemophilia A with factor VIII inhibitor.
    Mahasandana C; Suvatte V; Tanphaichitr VS; Bejrachandra S; Chandanayingyong D
    J Med Assoc Thai; 1988 Mar; 71(3):154-8. PubMed ID: 3133440
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII.
    Koshihara K; Qian J; Lollar P; Hoyer LW
    Blood; 1995 Sep; 86(6):2183-90. PubMed ID: 7662967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of hemophilia A treatment: factor VIII inhibitors.
    Kasper CK
    Ann N Y Acad Sci; 1991; 614():97-105. PubMed ID: 1902643
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-factor VIII antibodies (Inhibitors) in hemophilia A: in dire need of basic and therapeutic research.
    Kaveri SV
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):55-7. PubMed ID: 19153680
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitor to factor VIII in mild haemophilia.
    Kesteven PJ; Holland LJ; Lawrie AS; Savidge GF
    Thromb Haemost; 1984 Aug; 52(1):50-2. PubMed ID: 6437010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.
    Lacroix-Desmazes S; Wootla B; Dasgupta S; Delignat S; Bayry J; Reinbolt J; Hoebeke J; Saenko E; Kazatchkine MD; Friboulet A; Christophe O; Nagaraja V; Kaveri SV
    J Immunol; 2006 Jul; 177(2):1355-63. PubMed ID: 16818797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemical characterization of factor VIII inhibitors.
    Hoyer LW; Gawryl MS; de la Fuente B
    Prog Clin Biol Res; 1984; 150():73-85. PubMed ID: 6431443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
    Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
    Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A.
    Lacroix-Desmazes S; Misra N; Bayry J; Villard S; Kazatchkine MD; Kaveri SV
    J Immunol Methods; 2002 Nov; 269(1-2):251-6. PubMed ID: 12379365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adsorption of immunoglobulin G and anti-factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes.
    Cornelius RM; Dahri L; Boisson-Vidal C; Muller D; Jozefonvicz J; Brash JL
    Biomaterials; 1997 Mar; 18(5):429-36. PubMed ID: 9061184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitor assay using plasma F VIII versus recombinant F VIII--a comparative study.
    Hillman-Wiseman C; Vitale C; Lusher J
    Thromb Res; 1994 Oct; 76(2):221-4. PubMed ID: 7863471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.